



**CLEAN SYNTHESIS AND ANTIMICROBIAL INTERPRETATION OF AZO (DIPYRANO) AND BIS- CHALCONES DERIVATIVES FROM N-PHENYL PYRROLIDINE-2,5-DIONE AND N-PHENYL PIPERIDINE-2,6-DIONE**

**Dr Prashant P. Chaudhari\* and Dr Shankarsing S. Rajput**

*\*Department of Engineering Science, Dr. D. Y. Patil School of Engineering,*

*Dr. D.Y. Patil Knowledge City, Charoli (Bk), Lohegaon, Pune-412105.*

*E-mail: prashantchaudhari83@gmail.com*

*Department of Chemistry, SVS's Dadasaheb Rawal College, Dondaicha, Maharashtra, India*

**ABSTRACT**

The solvent-free synthesis of Azo (Dipyrano) derivatives was carried out with the help of PbO nanoparticles. They have been employed as an efficient catalyst (yields 81–91%) at room temperature using green chemistry and clean approach. PbO nanoparticles were established to be highly efficient, renewable and eco-friendly heterogeneous catalyst. PbO nanoparticles were prepared by hydro-thermal method. In the same manner a simple eco-friendly microwave instigated solvent free synthesis of bis-chalcones was carried out by the reaction of 1-(3-chlorophenyl)ethan-1-one with different substituted N-phenylpyrrolidine-2,5-dione or N-phenyl piperidine-2,6-dione in presence of neutral corundum (yields 85–90%). All the derivatives were characterized and interpreted for antimicrobial potencies.

**KEYWORDS**

Solvent free, pyrrolidine-2,5-dione, piperidine-2,6-dione, PbO nanoparticles.

**INTRODUCTION**

Benzo-pyrans and their derivatives are of appreciable importance because of their pharmacological activities<sup>i</sup>, such as anti-coagulant, spasmolytic, diuretic, anti-ancaphylactia and anti-cancer activities<sup>ii-v</sup>. In addition, they could act as cognitive enhancers and can be useful in the treatment of neuro-degenerative disease, Alzheimer's disease and Huntington's disease. Benzo-pyrans and their derivatives are also used for treatment of amyotrophic lateral sclerosis, AIDS associated dementia and Down's syndrome as well as schizophrenia and myoclonus<sup>vi,vii</sup>. The several biologically active natural products contain Benzo-pyrans and their derivatives<sup>viii</sup>. A number of Azo (Dipyrano) derivatives and 2-amino-4H-pyrans are helpful as pigments<sup>ix</sup>, photo-active material<sup>x</sup> and biodegradable agrochemicals<sup>xi</sup>. Hence a synthetic interest has

needed technological improvements for the original reaction conditions. The titled Azo (Dipyrano) derivatives are synthesized with the help of PbO nanoparticles by the reaction of cyclic imide with malononitrile in the presence of an appropriate substituted aromatic aldehyde. A variety of various reagents such as NaBr<sup>xii,xiii</sup>, KF-basic alumina under ultrasound irradiation<sup>xiv</sup>, hexadecyltrimethylammonium bromide (HTMAB)<sup>xv</sup>, amino-functionalized ionic liquid<sup>xvi</sup>, Na<sub>2</sub>SeO<sub>4</sub>, Ce(SO<sub>4</sub>)<sub>2</sub>.4H<sub>2</sub>O<sup>xvii</sup>, the use of microwave irradiation<sup>xviii</sup>, tetramethylammonium hydroxide (TMAH)<sup>xix</sup>, electrolysis<sup>xx</sup>, tetrabutylammonium bromide (TBABr)<sup>xxi</sup> and rare earth perfluorooctanoate RE(PFO)<sub>3</sub>, (S)-proline<sup>xxii,xxiii</sup> were signed up to catalyze these reactions.

Chalcones are the resourceful pioneer of heterocycle community and showed significant cytotoxic activities against cell line, breast cancer, human hepatocellular and lung carcinoma<sup>xxiv</sup>. They are potent microbial agents<sup>xxv-xxxvi</sup> and exhibit the synergetic antifungal and antibacterial, activities. They have shown considerable pharmacological activities like anti-mycobacterial activity against tuberculosis H37Rv<sup>xxxvii</sup>, anti-cancer<sup>xxxviii, xxxix</sup> in particular anti-breast cancer<sup>xl</sup>, anti-oxidant<sup>xli</sup>, antipyretic<sup>xlii</sup>, and anti-inflammatory<sup>xliii-xlv</sup>.


The titled bis-chalcones are synthesized with the help of catalyst Al<sub>2</sub>O<sub>3</sub> and microwave irradiation by the reaction of N-phenylpyrrolidine-2,5-dione or N-phenyl piperidine-2,6-dione with an appropriate substituted aromatic aldehyde. They could also be synthesized by the condensation<sup>xlvi</sup> of the substituted aldehyde, ketones and cyclic imide groups<sup>xlvii, xlviii</sup>. They could be also synthesized with the help of various types of synthetic routes like Knoevenagel condensation<sup>xlix</sup>, solid phase Claisen-Schmidt, acid catalyst, cross aldol condensation, coupling reaction<sup>l</sup>, and microwave assisted synthesis<sup>li-liv</sup>.

**EXPERIMENTAL:** Melting points were recorded in open glass capillaries and were uncorrected. The chemical structures of the obtained compounds were confirmed by spectral analyses. IR spectra in KBr pallets were obtained on Simadzu and ATR Bruker alpha FT-IR spectrophotometer. <sup>1</sup>H NMR spectra were obtained on and 500.13 MHz by Bruker spectrophotometer. The chemical shifts were reported as parts per million (ppm) with (CH<sub>3</sub>)<sub>4</sub>Si (TMS) as an internal standard. Signal multiplicities are represented by: s (singlet), d (doublet), t (triplet), m (multiplet). The purity of compound was checked by thin layer chromatography which was performed by using pre-coated silica gel aluminium plates with mixture of diethyl ether and ethyl acetate 7:3 proportion. Anti-microbial and Anti-fungal activities were carried out by Agar diffusion assay (Disk diffusion method, Disk size 6mm). PbO nanoparticle were synthesized by taking a mixture of 10 ml of 0.1N sodium hydroxide and 0.025 mole citric acid in distilled water was added to methanolic solution of 0.02 mole lead nitrate. The reaction mixture was continuously stirred with the help of magnetic stirrer for 2 hours at room temperature. The white polycrystalline product was obtained which is filtered, washed with distilled water and dried at 110<sup>o</sup>C for 2 hours. The dried solid product was calcinized at 500<sup>o</sup>C for 2 hours. During this process, the PbO nanoparticle which has white colour earlier turned to pale yellow colour. All the compounds (6a-f and 10a-f) were synthesized from the corresponding succinic and glutaric anhydride derivatives and commercially purchased p-fluorobenzaldehyde, neutral alumina (Al<sub>2</sub>O<sub>3</sub>) and ethanol.

### General Procedure of synthesis


#### Preparation of Azo (Dipyrano): 2,7-diamino-4,5-bis(2-chlorophenyl)-9-(N-methylpyridin-2-yl)-5,9-dihydro-4H-dipyrano[2,3-b:3',2'-d]pyrrole-3,6-dicarbonitrile (6a-c):

A mixture of 0.01 mole N-phenylpyrrolidine-2,5-dione, 0.02 mole aromatic aldehydes, 0.02 mole malononitrile and 100 mg PbO nanoparticles were ground at a room temperature with a mortar and pestle. The reaction was monitored by thin layer chromatography (TLC). After completion of reaction, the product was washed with distilled water. The novel developed compounds were dried and recrystallized from ethanol to afford pure compounds with high yield (Scheme – I).



#### Preparation of Azo (Dipyrano): 2,8-diamino-4,6-bis(2-chlorophenyl)-10-(N-methylpyridin-2-yl)-6,10-dihydro-4H,5H-dipyrano[2,3-b:3',2'-e]pyridine-3,7-dicarbonitrile (6d-f):


A mixture of 0.01 mole N-phenyl piperidine-2,6-dione, 0.02 mole aromatic aldehydes, 0.02 mole malononitrile and 100 mg PbO nanoparticles were ground at a room temperature with a mortar and pestle. The reaction was monitored by thin layer chromatography (TLC). After completion of reaction, the product was washed with distilled water. The novel developed compounds were dried and recrystallized from ethanol to afford pure compounds with high yield (Scheme – II).



**General Procedure of Synthesis:**


**Preparation of Chalcone: 3,4-bis((E)-2-chlorobenzylidene)-1-(N-methylpyridin-2-yl)pyrrolidine-2,5-dione (10a-c):**

The bis-chalcones (10a-c) derivatives were synthesized by the mixture of 0.01 mole of N-phenylpyrrolidine-2,5-dione and 0.02 mole of aromatic aldehyde in 1 gm of neutral  $Al_2O_3$  with the help of microwave irradiations. This mixture is maintained in microwave at 800W power for 4-6 minutes in solvent free condition. The novel developed compounds were recrystallized from ethanol (Scheme – III).



**Preparation of Chalcone: 3,5-bis((E)-2-chlorobenzylidene)-1-(N-methylpyridin-2-yl)piperidine-2,6-dione (10d-f):**

The bis-chalcones (10d-f) derivatives were synthesized by the mixture of 0.01 moles of N-phenylpiperidine-2,6-dione and 0.02 mole of aromatic aldehyde in 1 gm of neutral  $Al_2O_3$  with the help of microwave irradiations. This mixture is maintained in microwave at 800W power for 5-8 minutes in solvent free condition. The novel developed compounds were recrystallized from ethanol (Scheme – IV).



## RESULTS AND DISCUSSION:

### Chemistry:

The series of Azo (Dipyrano) derivatives 6a-f were synthesized by the reaction of different substituted N-phenylpyrrolidine-2,5-dione or N-phenyl piperidine-2,6-dione, 1-(3-chlorophenyl)ethan-1-one and malononitrile with the help of PbO nanoparticles. The formation of Azo (Dipyrano) derivatives was confirmed by IR, <sup>13</sup>CNMR and <sup>1</sup>HNMR and elemental analysis. The series of bis-chalcones derivatives 10a-f were synthesized by the reaction of 1-(3-chlorophenyl)ethan-1-one with different substituted N-phenylpyrrolidine-2,5-dione or N-phenyl piperidine-2,6-dione in presence of neutral Al<sub>2</sub>O<sub>3</sub> with the help of microwave irradiations. The formation of bis-chalcones was confirmed by IR, <sup>13</sup>CNMR and <sup>1</sup>HNMR and elemental analysis.

#### **2,7-diamino-4,5-bis(2-chlorophenyl)-9-(5-methylpyridin-2-yl)-5,9-dihydro-4H-dipyranol[2,3-b:3',2'-d]pyrrole-3,6-dicarbonitrile(6a)**

Sulfur Yellow Solid, Yield (87.96%), M. P. 186-88°C, M.F. C<sub>30</sub>H<sub>20</sub>Cl<sub>2</sub>O<sub>2</sub>N<sub>6</sub>, M.W. 567.42; Composition: Cal: C(63.50%) H(3.55%) N(14.81%); Obs: C(63.70%) H(3.67%) N(14.47%); IR-(KBr): -C-Cl: 613.70; C≡N: 2223.99; -N-H: 3095.16; aromatic ring (2-Peaks): 3030.44, 660.79; -CH<sub>3</sub>: 2968.20; >C=C<: 1741.26, C-O: 1091.09; C-N (Aliphatic): 1005.32; C-N (Aromatic): 1288.43; -C-C- Stretch in a ring (3-Peaks): 1579.86, 1548.05, 1406.17; -CH<sub>3</sub> bend: 1487.56, 1372.27 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.37 (t, 4H, Ar-H, J=7.39), 7.42 (t, 4H, Ar-H, J=7.34), 4.77 (s, 2H, methine), 6.81 (s, 4H, -NH<sub>2</sub>), 8.53 (d, 1H, pyridine, J=7.44), 7.34 (t, 1H, pyridine, J=7.34), 7.42 (t, 1H, pyridine), 2.45 (s, 3H, CH<sub>3</sub>-pyridine).

#### **2,7-diamino-4,5-bis(2-chlorophenyl)-9-(4-methylpyridin-2-yl)-5,9-dihydro-4H-dipyranol[2,3-b:3',2'-d]pyrrole-3,6-dicarbonitrile(6b)**

Vanilla Solid, Yield (89.88%), M. P. 196-98°C, M.F. C<sub>30</sub>H<sub>20</sub>Cl<sub>2</sub>O<sub>2</sub>N<sub>6</sub>, M.W. 567.42; Composition: Cal: C(63.50%) H(3.55%) N(14.81%); Obs: C(63.67%) H(3.37%) N(14.58%); IR-(KBr): -C-Cl: 610.55; C≡N: 2224.85; -N-H: 3094.02; aromatic ring (2-Peaks): 3031.41, 661.25; -CH<sub>3</sub>: 2966.72; >C=C<: 1742.51, C-O: 1092.13; C-N (Aliphatic): 1004.53; C-N (Aromatic): 1280.43; -C-C- Stretch in a ring (3-Peaks): 1580.22, 1547.19, 1405.75; -CH<sub>3</sub> bend: 1480.22, 1370.61 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.37 (t, 4H, Ar-H, J=7.39), 7.42 (t, 4H, Ar-H, J=7.34), 4.77 (s, 2H, methine), 6.81 (s, 4H, -NH<sub>2</sub>), 8.53 (d, 1H, pyridine, J=7.44), 7.34 (t, 1H, pyridine, J=7.34), 7.42 (t, 1H, pyridine), 2.45 (s, 3H, CH<sub>3</sub>-pyridine).

#### **2,7-diamino-4,5-bis(2-chlorophenyl)-9-(6-methylpyridin-2-yl)-5,9-dihydro-4H-dipyranol[2,3-b:3',2'-d]pyrrole-3,6-dicarbonitrile(6c)**

Vanilla Solid, Yield (93.06%), M. P. 198-200°C, M.F. C<sub>30</sub>H<sub>20</sub>Cl<sub>2</sub>O<sub>2</sub>N<sub>6</sub>, M.W. 567.42; Composition: Cal: C(63.50%) H(3.55%) N(14.81%); Obs: C(63.62%) H(3.73%) N(14.32%); IR-(KBr): -C-Cl: 611.39; C≡N: 2223.51; -N-H: 3096.23; aromatic ring (2-Peaks): 3031.98, 660.88; -CH<sub>3</sub>: 2970.23; >C=C<: 1741.95, C-O: 1091.87; C-N (Aliphatic): 1007.43; C-N (Aromatic): 1289.52; -C-C- Stretch in a ring (3-Peaks): 1581.34, 1546.93, 1406.00; -CH<sub>3</sub> bend: 1479.08, 1369.55 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.30 (t, 4H, Ar-H, J=7.53), 7.40 (t, 4H, Ar-H, J=7.33), 4.80 (s, 2H, methine), 6.73 (s, 4H, -NH<sub>2</sub>), 7.90

(t, 1H, pyridine, J=7.44), 7.81 (t, 1H, pyridine, J=7.29), 6.98 (t, 1H, pyridine, J=7.25), 2.57 (s, 3H, CH<sub>3</sub>-pyridine).

**2,8-diamino-4,6-bis(2-chlorophenyl)-10-(5-methylpyridin-2-yl)-6,10-dihydro-4H,5H-dipyranol[2,3-b:3',2'-e]pyridine-3,7-dicarbonitrile (6d)**

Ivory ColorSolid, Yield (83.66%), M. P. 110-12°C, M.F. C<sub>31</sub>H<sub>22</sub>O<sub>2</sub>N<sub>6</sub>Cl<sub>2</sub>, M.W. 581.45; Composition: Cal:C(64.03%) H(3.81%)N(14.45%); Obs: C(64.36%) H(3.10%)N(14.99%); IR-(KBr): -C-Cl:616.10; C≡N:2226.52; -N-H: 3166.84; aromatic ring (2-Peaks): 3101.77, 653.55; -CH<sub>2</sub>: 3048.95; -CH<sub>3</sub>: 2932.79; >C=C<: 1622.05, C-O: 1043.27; C-N (Aliphatic): 1128.69; C-N (Aromatic): 1173.66; -C-C- Stretch in a ring(3-Peaks): 1581.06, 1544.83, 1497.28; -CH<sub>3</sub> bend: 1439.06, 1379.21; -CH<sub>2</sub> bend: 1462.80 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.60 (t, 2H, Ar-H, J=7.29), 7.24 (m, 2H, Ar-H, J=7.40), 7.25 (m, 2H, Ar-H, J=7.60), 7.35 (t, 2H, Ar-H, J=7.49), 3.87 (s, 2H, methine), 3.17 (s, 2H, -CH<sub>2</sub>), 6.78 (s, 4H, -NH<sub>2</sub>), 7.88 (d, 1H, pyridine), 7.41 (t, 1H, pyridine, J=7.61), 6.90 (d, 1H, pyridine, J=7.65), 2.13 (s, 3H, CH<sub>3</sub>-pyridine).

**2,8-diamino-4,6-bis(2-chlorophenyl)-10-(4-methylpyridin-2-yl)-6,10-dihydro-4H,5H-dipyranol[2,3-b:3',2'-e]pyridine-3,7-dicarbonitrile (6e)**

Saffron Yellow ColorSolid, Yield (89.43%), M. P. 158-60°C, M.F. C<sub>31</sub>H<sub>22</sub>O<sub>2</sub>N<sub>6</sub>Cl<sub>2</sub> M.W. 581.45; Composition: C(64.03%) H(3.81%)N(14.45%); Obs: C(64.45%) H(3.03%)N(14.85%); IR-(KBr): -C-Cl:616.78; C≡N:2226.02; -N-H: 3164.22; aromatic ring (2-Peaks): 3100.36, 652.81; -CH<sub>2</sub>: 3048.18; -CH<sub>3</sub>: 2934.50; >C=C<: 1628.09, C-O: 1045.58; C-N (Aliphatic): 1130.13; C-N (Aromatic): 1153.81; -C-C- Stretch in a ring(3-Peaks): 1580.73, 1516.34, 1490.42; -CH<sub>3</sub> bend: 1402.48, 1372.11; -CH<sub>2</sub> bend: 1438.54 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.58 (t, 2H, Ar-H, J=7.33), 7.27 (m, 2H, Ar-H, J=7.44), 7.16 (m, 2H, Ar-H, J=7.50), 7.31 (t, 2H, Ar-H, J=7.42), 3.91 (s, 2H, methine), 3.11 (s, 2H, -CH<sub>2</sub>), 6.85 (s, 4H, -NH<sub>2</sub>), 7.79 (d, 1H, pyridine, J=7.56), 7.01 (t, 1H, pyridine, J=7.51), 6.88 (d, 1H, pyridine), 2.27 (s, 3H, CH<sub>3</sub>-pyridine).

**2,8-diamino-4,6-bis(2-chlorophenyl)-10-(6-methylpyridin-2-yl)-6,10-dihydro-4H,5H-dipyranol[2,3-b:3',2'-e]pyridine-3,7-dicarbonitrile (6f)**

Luminous Bright Orange ColorSolid, Yield (86.54%), M. P. 90-92 °C, M.F. C<sub>31</sub>H<sub>22</sub>O<sub>2</sub>N<sub>6</sub>Cl<sub>2</sub>, M.W. 581.45; Composition: C(64.03%) H(3.81%)N(14.45%); Obs: C(64.71%) H(3.19%)N(14.83%); IR-(KBr): -C-Cl:616.47; C≡N:2225.69; -N-H: 3163.15; aromatic ring (2-Peaks): 3098.59, 651.92; -CH<sub>2</sub>: 3048.32; -CH<sub>3</sub>: 2932.76; >C=C<: 1694.30, C-O: 1045.28; C-N (Aliphatic): 1131.31; C-N (Aromatic): 1162.77; -C-C- Stretch in a ring(3-Peaks): 1580.57, 1509.74, 1489.57; -CH<sub>3</sub> bend: 1404.02, 1372.81; -CH<sub>2</sub> bend: 1438.93 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.70 (t, 2H, Ar-H, J=7.47), 7.32 (m, 2H, Ar-H, J=7.61), 7.15 (m, 2H, Ar-H, J=7.65), 7.37 (t, 2H, Ar-H, J=7.55), 3.89 (s, 2H, methine), 3.09 (s, 2H, -CH<sub>2</sub>), 6.87 (s, 4H, -NH<sub>2</sub>), 6.80 (t, 1H, pyridine, J=7.67), 7.57 (t, 1H, pyridine, J=7.63), 6.61 (t, 1H, pyridine, J=7.70), 2.50 (s, 3H, CH<sub>3</sub>-pyridine).

**3,4-bis((E)-2-chlorobenzylidene)-1-(5-methylpyridin-2-yl)pyrrolidine-2,5-dione(10a)**

Red Brown Solid, Yield (83.35%), M. P. 282-84 °C, M.F. C<sub>24</sub>H<sub>16</sub>O<sub>2</sub>N<sub>2</sub>Cl<sub>2</sub>, M.W. 435.30; Composition: Cal:C(67.41%) H(3.77%)N(15.72%); Obs: C(67.82%) H(3.43%)N(15.33%); IR-(KBr): -C-Cl: 638.81; >C=C<: 1591.22; >C=O: 1711.64; aromatic ring (3-Peaks): 3021.88,

997.57, 829.29; -CH<sub>3</sub>: 2940.87; C-N (Aliphatic): 1185.37; C-N (Aromatic): 1298.82; -C-C- Stretch in a ring: 1591.22; -CH<sub>3</sub> bend: 1456.35, 1384.27 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.48 (t, 2H, Ar-H, J=7.40), 6.98 (m, 2H, Ar-H, J=7.28), 7.18 (m, 2H, Ar-H, J=7.40), 7.22 (t, 2H, Ar-H, J=7.36), 8.04 (s, 2H, ethylene), 7.90 (d, 1H, pyridine), 7.54 (t, 1H, pyridine, J=7.51), 7.40 (d, 1H, pyridine), 2.19 (s, 3H, CH<sub>3</sub>-pyridine).

**3,4-bis((E)-2-chlorobenzylidene)-1-(4-methylpyridin-2-yl)pyrrolidine-2,5-dione(10b)**

Pearl Copper Solid, Yield (82.41%), M. P. 260-62 °C, M.F. C<sub>24</sub>H<sub>16</sub>O<sub>2</sub>N<sub>2</sub>Cl<sub>2</sub>, M.W. 435.30; Composition: Cal:C(67.41%) H(3.77%)N(15.72%); Obs: C(67.65%) H(3.57%)N(15.39%); IR-(KBr): -C-Cl: 630.12; >C=C<: 1593.53; >C=O: 1715.27; aromatic ring (3-Peaks): 3022.62, 990.34, 820.17; -CH<sub>3</sub>: 2931.79; C-N (Aliphatic): 1170.14; C-N (Aromatic): 1270.26; -C-C- Stretch in a ring: 1594.08; -CH<sub>3</sub> bend: 1455.87, 1380.65 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.48 (t, 2H, Ar-H, J=7.40), 7.01 (m, 2H, Ar-H, J=7.30), 7.19 (m, 2H, Ar-H, J=7.43), 7.24 (t, 2H, Ar-H, J=7.39), 8.01 (s, 2H, ethylene), 7.89 (d, 1H, pyridine), 7.37 (d, 1H, pyridine), 7.26 (t, 1H, pyridine, J=7.45), 2.24 (s, 3H, CH<sub>3</sub>-pyridine).

**3,4-bis((E)-2-chlorobenzylidene)-1-(6-methylpyridin-2-yl)pyrrolidine-2,5-dione(10c)**

Fawn Brown Solid, Yield (79.01%), M. P. 304-06 °C, M.F. C<sub>24</sub>H<sub>16</sub>O<sub>2</sub>N<sub>2</sub>Cl<sub>2</sub>, M.W. 435.30; Composition: Cal:C(67.41%) H(3.77%)N(15.72%); Obs: C(67.31%) H(3.55%)N(15.37%); IR-(KBr): -C-Cl: 632.23; >C=C<: 1590.05; >C=O: 1709.32; aromatic ring (3-Peaks): 3025.16, 925.09, 815.51; -CH<sub>3</sub>: 2928.13; C-N (Aliphatic): 1176.66; C-N (Aromatic): 1225.73; -C-C- Stretch in a ring: 1611.28; -CH<sub>3</sub> bend: 1458.29, 1379.43 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.47 (t, 2H, Ar-H, J=7.47), 7.02 (m, 2H, Ar-H, J=7.32), 7.20 (m, 2H, Ar-H, J=7.41), 7.26 (t, 2H, Ar-H, J=7.39), 8.05 (s, 2H, ethylene), 6.83 (t, 1H, pyridine, J=7.34), 7.59 (t, 1H, pyridine, J=7.38), 7.35 (t, 1H, pyridine, J=7.34), 2.41 (s, 3H, CH<sub>3</sub>-pyridine).

**3,5-bis((E)-2-chlorobenzylidene)-1-(5-methylpyridin-2-yl)piperidine-2,6-dione (10d)**

Khaki Grey Solid, Yield (83.17%), M. P. 308-10 °C, M.F. C<sub>25</sub>H<sub>18</sub>O<sub>2</sub>N<sub>2</sub>Cl<sub>2</sub>, M.W. 449.32; Composition: Cal:C(66.83%) H(4.04%)N(6.23%); Obs: C(67.02%) H(3.93%)N(6.89%); IR-(KBr): -C-Cl: 652.36; >C=C<: 1595.07; >C=O: 1704.07; aromatic ring (3-Peaks): 3027.09, 835.44, 749.26; -CH<sub>3</sub>: 2968.07; -CH<sub>2</sub>: 2930.11; C-N (Aliphatic): 1175.55; C-N (Aromatic): 1272.19; -C-C- Stretch in a ring: 1595.07, 1545.30; -CH<sub>3</sub> bend: 1425.29, 1386.12; -CH<sub>2</sub> bend: 1466.66 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.43 (t, 2H, Ar-H, J=7.38), 6.99 (m, 2H, Ar-H, J=7.27), 7.21 (m, 2H, Ar-H, J=7.35), 7.27 (t, 2H, Ar-H, J=7.40), 7.45 (d, 2H, ethylene), 2.60 (t, 2H, methylene), 7.92 (d, 1H, pyridine), 7.51 (t, 1H, pyridine, J=7.54), 7.43 (d, 1H, pyridine), 2.20 (s, 3H, CH<sub>3</sub>-pyridine).

**3,5-bis((E)-2-chlorobenzylidene)-1-(4-methylpyridin-2-yl)piperidine-2,6-dione (10e)**

Clay Brown Solid, Yield (76.73%), M. P. 262-64 °C, M.F. C<sub>25</sub>H<sub>18</sub>O<sub>2</sub>N<sub>2</sub>Cl<sub>2</sub>, M.W. 449.32; Composition: Cal:C(66.83%) H(4.04%)N(6.23%); Obs: C(66.29%) H(4.66%)N(6.91%); IR-(KBr): -C-Cl: 662.33; >C=C<: 1571.06; >C=O: 1739.10; aromatic ring (3-Peaks): 3025.45, 793.37, 688.37; -CH<sub>3</sub>: 2944.95; -CH<sub>2</sub>: 2931.27; C-N (Aliphatic): 1044.84; C-N (Aromatic): 1224.37; -C-C- Stretch in a ring: 1618.68, 1571.06; -CH<sub>3</sub> bend: 1416.61, 1372.61; -CH<sub>2</sub> bend: 1461.01 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.44 (t, 2H, Ar-H, J=7.42), 7.03 (m, 2H, Ar-H, J=7.27), 7.22 (m, 2H, Ar-H, J=7.47), 7.29 (t, 2H, Ar-H, J=7.33), 7.47 (d, 2H, ethylene), 2.59 (t,

2H, methylene), 7.88 (d, 1H, pyridine), 7.38 (d, 1H, pyridine), 7.22 (t, 1H, pyridine, J=7.48), 2.25 (s, 3H, CH<sub>3</sub>-pyridine).

**3,5-bis((E)-2-chlorobenzylidene)-1-(6-methylpyridin-2-yl)piperidine-2,6-dione (10f)**

Olive Brown Solid, Yield (91.58%), M. P. 258-60 °C, M.F. C<sub>25</sub>H<sub>18</sub>O<sub>2</sub>N<sub>2</sub>Cl<sub>2</sub>, M.W.449.32; Composition: Cal:C(66.83%) H(4.04%)N(6.23%); Obs: C(66.57%) H(4.30%)N(6.80%); IR (KBr): -C-Cl: 660.47; >C=C<: 1596.51;>C=O:1728.19; aromatic ring (3-Peaks): 3026.32, 790.35, 743.67; -CH<sub>3</sub>: 2947.83; -CH<sub>2</sub>: 2933.43; C-N (Aliphatic): 1170.67; C-N (Aromatic): 1270.80; -C-C- Stretch in a ring: 1609.23, 1565.56; -CH<sub>3</sub> bend: 1425.82, 1380.16; -CH<sub>2</sub> bend: 1467.73 cm<sup>-1</sup>; <sup>1</sup>H NMR (500.13 MHz, DMSO, δ ppm): 7.45 (t, 2H, Ar-H, J=7.41), 7.04 (m, 2H, Ar-H, J=7.30), 7.23 (m, 2H, Ar-H, J=7.45), 7.30 (t, 2H, Ar-H, J=7.50), 7.46 (d, 2H, ethylene), 2.61 (t, 2H, methylene), 6.85 (t, 1H, pyridine, J=7.36), 7.61 (t, 1H, pyridine, J=7.40), 7.33 (t, 1H, pyridine, J=7.33), 2.43 (s, 3H, CH<sub>3</sub>-pyridine).

**Antimicrobial Activities:**

All the synthesized Azo (Dipyran) derivatives 6a-f and bis-chalcones derivatives 10a-f were screened for their antibacterial activity against gram positive bacteria *Staphylococcus aureus* (NCIM 2079), *Bacillus subtilis* (NCIM 2250) and gram negative bacteria *Escherichia coli* (NCIM 2109), *Pseudomonas aeruginosa* (NCIM 2036) using DMSO solvent. All these novel synthesized compounds were screened against Fungi (Yeast) *Candida albicans* (NCIM 3471) and *Aspergillus niger* (NCIM 545). The bacterial cultures were purchased from NCIM: National Collection of Industrial Microorganisms, National Chemical Laboratory (NCL), Pune 411008 [India]. Some of the compounds showed moderate to good activities against gram positive bacteria *S. aureus*, *B. subtilis* and synergetic activities against Fungi *C. albicans* and *A. niger* as shown in the Table-I, II and Graph-I, II;

**Table-I**


**Antimicrobial activities of Azo (Dipyran) derivatives 6a-f**

Sr. No.	Sample	E. coli	P. aeruginosa	S. aureus	B. subtilis	C. albicans	A. niger
		Mean±SD	Mean ±SD	Mean ±SD	Mean ±SD	Mean ±SD	Mean ±SD
1	6a	7.45±0.07	- - -	16.16±0.06	11.67±0.17	21.31±0.08	19.7±0.17
2	6b	7.98±0.17	- - -	20.45±0.08	13.04±0.08	21.32±0.11	18.9±0.07
3	6c	- - -	- - -	16.07±0.13	14.23±0.09	19.76±0.18	19.7±0.04
4	6d	- - -	- - -	12.26±0.06	10.92±0.10	18.79±0.13	20.3±0.17
5	6e	- - -	- - -	13.03±0.18	12.42±0.14	20.16±0.07	20.2±0.10
6	6f	- - -	- - -	15.8±0.13	10.63±0.16	19.19±0.33	20.4±0.21
	<b>Choromphenicol</b>	<b>24.09±0.1</b>	<b>14.39±0.07</b>	<b>23.92±0.17</b>	<b>28.43±0.29</b>	NA	NA
	<b>Amphotericin B</b>	NA	NA	NA	NA	<b>15.21±0.15</b>	<b>11.8±0.08</b>




**Table-II**  
**Antimicrobialactivities ofbischalcone derivatives 10a-f**

Sr. No.	Sample	E. coli	P. aeruginosa	S. aureus	B. subtilis	C. albicans	A. niger
		Mean±SD	Mean ±SD	Mean ±SD	Mean ±SD	Mean ±SD	Mean±SD
1	10a	- - -	- - -	11.34±0.31	7.07±0.06	- - -	20.5±0.09
2	10b	- - -	- - -	- - -	8.28±0.04	- - -	20.2±0.07
3	10c	- - -	- - -	- - -	- - -	- - -	13.2±0.07
4	10d	- - -	- - -	- - -	- - -	- - -	9.81±0.11
5	10e	- - -	- - -	- - -	7.80±0.10	- - -	15.2±0.02
6	10f	- - -	- - -	8.66±0.22	9.93±0.22	- - -	12.7±0.22
	<b>Choramphenicol</b>	<b>24.09±0.1</b>	<b>14.39±0.07</b>	<b>23.92±0.17</b>	<b>28.43±0.29</b>	NA	NA
	<b>Amphotericin B</b>	NA	NA	NA	NA	<b>15.21±0.15</b>	<b>11.8±0.08</b>



Graph-I:AntimicrobialactivitiesofAzo (Dipyran) derivatives 6a-f.



Graph-II: Antimicrobial activities of bischalcone derivatives 10a-f.

## REFERENCES:

- i. Green G. R., Evans J. M. and Vong A. K.; *Comprehensive Heterocyclic Chemistry* Katritzky A. R., Rees C. W., Scriven E. F. V; Ed., Pergamon Press: Oxford, 5,(1995), 469.
- ii. Witte E. C., Neubert P. and Roesch A.; *ChemAbstr.*, 104, (1986) 224915f.
- iii. Zhang Y. L., Chen B. Z., Zheng K. Q., Xu M. L. and Lei X. H.; *ChemAbstr.*, 96,(1982), 135383e.
- iv. Zhang Y. L., Chen B. Z., Zheng K. Q., Xu M. L., Zhang L. Z. and Lei X. H.; *Yao XueXueBao.*, 17(1), 1722,(1982), 534.
- v. Andreani L. L. and Lapi E.; *Bull Chim Fr.*, 99,(1960), 583.
- vi. Konkoy S., Fick D. B., Cai S. X., Lan N. C. and Keana J. F. W.; *PCT IntAppl WO 0075123 ChemAbstr.*, 134, (2000), 29313a.
- vii. Konkoy C. S., Fick D. B., Cai S. X., Lan N. C. and Keana J. F. W.; *PCT IntAppl WO, 0075, (2000),123.*
- viii. Hatakeyama S., Ochi N., Numata H. and Takano S.; *JChemSocChemCommun.*,(1988), 1202-1204.
- ix. Ellis G. P., Weissberger A. and Taylor E. C.; *The Chemistry of Heterocyclic Compounds Chromenes*, Wiley, New York, 31,(1977), 121.
- x. Arnesto D., Horspool W. M., Martin N., Ramos A. and Seane C.; *J Org Chem.*, 54, (1989), 3069-3072.
- xi. Hafez E. A. A., Elnagdi M. H., Elagamey A. G. A. and Eltaweel F. M. A. A.; *Heterocycl.*, 26, (1987), 903-907.

- xii. Devi I. and Bhuyan P. J.; *Tetrahedron lett.*,45, (2004), 8625-8627.
- xiii. Wang L. M., Shao J. H., Tian H., Wang Y. H. and Liu B.; *J Fluorine Chem.*, 127,(2006), 97-100.
- xiv. Wang X. S., Shi D. Q., Tu S. J. and Yao C. S.; *Synth Commun.*,33, (2003), 119-126.
- xv. Jin T. S., Wang A. Q., Wang X., Zhang J. S. and Li T. S.;*Synlett.*, 1, (2004), 871-873.
- xvi. Peng Y. Q. and Song G. H.;*CatalCommun.*,8, (2007), 111-114.
- xvii. Islami M. R. and Mosaddegh E.; *Phosphorus, Sulfur Silicon Relat Elem.*, 184, (2009), 3134-3138.
- xviii. Tu S. J., Gao Y., Guo C., Shi D. and Lu Z.; *Synth Commun.*, 32, (2002), 2137-2141.
- xix. Balalaie S., Sheikh-Ahmadi M. and Bararjanian M.;*CatalCommun.*, 8,(2007),1724–1728.
- xx. Fotouhi L., Heravi M. M., Fatehi A. and Bakhtiari K., *Tetrahedron Lett.*,48, (2007), 5379-5381.
- xxi. Gurumurthi S., Sundari V. and Valliappan R.; *E-J Chem.*, 6S1, (2009), S466-S472.
- xxii. Balalaie S., Bararjanian M., Amani A. M. and Movassagh B.;*Synlett.*,1 (2006), 263-266.
- xxiii. Hekmatshoar R., Majedi S. and Bakhtiari K.;*CatalCommun.*, 9, (2008), 307-310.
- xxiv. Hieu B. T., Thuy L. T., Thuy V. T., Tien H. X., Chinh L. V., Hoang V. D. and Vu T. K.; *Bull. Korean Chem. Soc.*, 33(5), (2012),1586-1592.
- xxv. Sharma B. K., Ameta S. C. and Dwivedi V. K.; *International Journal of Chemical Sci.*, 12(4), (2014), 1121-1134.
- xxvi. Chauhan A., Sharma P. K., Kaushik N. and Kumar N.; *International Journal of Pharmacy and Pharmaceutical Sciences*, 3(5), (2011), 166-176.
- xxvii. Bhanat K., Parashar B. and Sharma V. K.; *Research Journal of Chemical Sciences*, 4(2), (2014), 68-74.
- xxviii. Kotla V. V., Dalavai V. K. and Chunduri V. R.; *Der Pharma Chemica*, 4(5), (2012), 2003-2008.
- xxix. Yadav A. K., Singh V. and Singh D.; *Asian Journal of Chemistry*, 19(5), (2007), 3511-3514.
- xxx. Shah S. H. and Patel P. S., *Research Journal of Chemical Sciences*, 2(7), (2012), 62-68.
- xxxi. Kumar C., and Reddy V.; *International Journal of Scientific and Research Publications*, 3(5), (2013), 1-7.
- xxxii. Mallikarjuna Rao R., Sreeramulu J., Ravindranath L. K., Nagaraja Reddy G., Hanumantharayudu K., Nageswara Reddy G., Jayaraju A. and Madhusudhan P.; *Journal of Chemical and Pharmaceutical Research*, 4(1), (2012), 272-278.
- xxxiii. Baluja S. and Chanda S.; *World Research Journal of Biochemistry*, 1(1), (2012), 6-10.
- xxxiv. Azarifar D. and Shaebanzadeh M.; *Molecules*, 7, (2002),885-895.
- xxxv. Swarnkar D., Ameta R. and Vyas R.; *International Research Journal of Pharmacy*, 5(6), (2014), 459-462.
- xxxvi. Sharshira E. M. and Hamada N. M. M.; *Molecules*, 17, (2012), 4962-49.
- xxxvii. Azarifar D. and Shaebanzadeh M.; *Molecules*, 7, (2002),885-895.
- xxxviii. Ozdemir A., Tarun-Zitouni G. and Kaplancikli Z. A.; *Turk Journal of Chemistry*,32, (2008), 529-538.
- xxxix. Kalirajan R., Rathore L., Gowramma B., Gomathy S. and Sankar S.; *Indian Journal of Chemistry*, 50(B), (2011),1794-1799.
- xl. Goyal A., Jain N. and Jain S.; *Der Pharmacia Sinica*, 4(4), (2013), 112-117.

- xli. Fouad S. A.; International Journal of Advanced Research, 2(12), (2014),442-453.
- xlii. Kumar G. V., Govindraju M., Renuka N., Khatoon B. B. A., Mylarappa B. N. and Kumar K.A.; RASAYAN J. Chem., 5(3), (2012), 338-342.
- xliii. Pasin J.S.M., Ferreira A.P.O., Saraiva A.L.L., Ratzlaff V., Andrighetto R., Machado P., Marchesan S., Zanette R.A., Bonacorso H.G., Zanatta N., Martins M.A.P., Ferreira J. and Mello C. F.; Braz J Med Biol Res, 43(12), (2010), 1193-1202.
- xliv. Jadhav S. Y., Bhosale R. B., Shirame S. P., Sonawane V. D., Hublikar M. G., Sonawane K. D. and Shaikh R. U.; Int. J. Pharm Bio. Sci., 4(2), (2013), 390-397.
- xlv. Prasanna Raja P., Riyazulah M.S. and Kumar V. S., International Journal of ChemTech Research, 2(4), (2010),1998-2004.
- xlvi. Malhotra P., Pathan S. and Nikalje A. P.; International Journal of Pharmacy and Pharmaceutical Sciences, 2(2), (2010), 21-26.
- xlvii. Voskiene A., Mickevicius V. and Mikulskiene G.; ARKIVOC, (xv), (2007), 303-314.
- xlviii. Dhivare R. S. and Rajput S. S.; International Journal of Chemistry and Pharmaceutical Sciences, 3 (8), (2015), 1877-1880.
- xlix. Dhivare R. S. and Rajput S. S.; World Journal of Pharmaceutical Research, 4(6), (2015), 1650-1658.
- l. Rajput S. S.; International Journal of Advances in Pharmacy, Biology and Chemistry, 1 (2), (2012), 242-246.
- li. Patil C. B., Mahajan S. K. and Katti S. A.; Journal of Pharmaceutical Science and Research, 1(3), (2009), 11-22.
- lii. Ghosh R. and Das A.; World Journal of Pharmacy and Pharmaceutical Sciences, 3 (3), (2014), 578-595.
- liii. Khalaf M. I., Abdel-Wahab A. and Kandil F.; Iraqi Journal of Science, 53(1), (2012), 17-24.
- liv. Suwito H., Jumina, Mustofa, Kristanti A. N. and Puspaningsih N. N. T.; Journal of Chemical and Pharmaceutical Research, 6(5), (2014), 1076-1088.

Received on November 17, 2017.